Atea Pharmaceuticals Current Assets Trend from 2010 to 2021

AVIR -  USA Stock  

USD 25.03  1.02  3.92%

Atea Pharmaceuticals Current Assets yearly trend continues to be relatively stable with very little volatility. Current Assets are likely to grow to about 931.6 M this year. During the period from 2010 to 2021, Atea Pharmaceuticals Current Assets destribution of quarterly values had r-value of  0.65 from its regression line and mean deviation of  240,039,561. As of 07/28/2021, Direct Expenses is likely to grow to about 1.4 M.

Search Historical Trends 

 
Refresh
Check Atea Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Atea Pharmaceuticals main balance sheet or income statement drivers, such as Direct Expenses of 1.4 M, Gross Profit of 43.5 M or Operating Expenses of 47.6 M, as well as many exotic indicators such as Long Term Debt to Equity of 0.0077, PPandE Turnover of 42.93 or Receivables Turnover of 13.11. Atea Pharmaceuticals financial statements analysis is a perfect complement when working with Atea Pharmaceuticals Valuation or Volatility modules. It can also supplement various Atea Pharmaceuticals Technical models. Please continue to the analysis of Atea Pharmaceuticals Correlation against competitors.

Atea Pharmaceuticals Quarterly Current Assets

840.14 MillionShare

Atea Pharmaceuticals Current Assets Breakdown

Showing smoothed Current Assets of Atea Pharmaceuticals with missing and latest data points interpolated. Current assets of Atea Pharmaceuticals include cash, cash equivalents, short-term investments, accounts receivable, stock inventory and the portion of prepaid liabilities which will be paid within a year. Depending on the nature of the business, current assets can range from barrels of crude oil, to baked goods, to foreign currency. Current assets are important because they are the assets that are used to fund day-to-day operations of Atea Pharmaceuticals. The current portion of Total Assets; reported if a company operates a classified balance sheet that segments current and non-current assets.Atea Pharmaceuticals' Current Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Atea Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 97.88 M10 Years Trend
Increasing
Slightly volatile
 Current Assets 
Share
      Timeline 

Atea Pharmaceuticals Current Assets Regression Statistics

Arithmetic Mean 177,442,936
Geometric Mean 57,421,387
Coefficient Of Variation 189.75
Mean Deviation 240,039,561
Median 34,698,000
Standard Deviation 336,700,690
Range 909,736,237
R-Value 0.65
R-Squared 0.42
Significance 0.023429
Slope 60,265,474

Atea Pharmaceuticals Current Assets History

201921.9 M
2020863.5 M
2021931.6 M

Other Fundumenentals of Atea Pharmaceuticals

Atea Pharmaceuticals Current Assets component correlations

About Atea Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Atea Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Atea Pharmaceuticals investors use historical funamental indicators, such as Atea Pharmaceuticals's Current Assets, to determine how well the company is positioned to perform in the future. Although Atea Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Atea Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Atea Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Atea Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Atea Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2021
Current Assets863.5 M931.6 M
Net Current Assets as percentage of Total Assets 107.56  102.91 
Average Assets442.9 M369.5 M
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts. Atea Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs people.

Atea Pharmaceuticals Investors Sentiment

The influence of Atea Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Atea Pharmaceuticals. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Current Sentiment - AVIR

Atea Pharmaceuticals Investor Sentiment

Macroaxis portfolio users are unresponsive in their sentiment towards investing in Atea Pharmaceuticals. What is your sentiment towards investing in Atea Pharmaceuticals? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Pair Trading with Atea Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Atea Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Atea Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Atea Pharmaceuticals Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Atea Pharmaceuticals and Equillium. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Please continue to the analysis of Atea Pharmaceuticals Correlation against competitors. Note that the Atea Pharmaceuticals information on this page should be used as a complementary analysis to other Atea Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.

Complementary Tools for Atea Pharmaceuticals Stock analysis

When running Atea Pharmaceuticals price analysis, check to measure Atea Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea Pharmaceuticals is operating at the current time. Most of Atea Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Atea Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Atea Pharmaceuticals' price. Additionally, you may evaluate how the addition of Atea Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Fund Screener
Find activelly-traded funds from around the world traded on over 30 global exchanges
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
The market value of Atea Pharmaceuticals is measured differently than its book value, which is the value of Atea Pharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of Atea Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Atea Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atea Pharmaceuticals' market value can be influenced by many factors that don't directly affect Atea Pharmaceuticals underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atea Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Atea Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atea Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.